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OBJECTIVE: To evaluate cost-effectiveness (CE) of three
drug therapies for preventing osteoporotic fractures in post-
menopausal women from a state Medicaid Program per-
spective using the estimated risk distribution in the study
population. The three therapies are: hormone replacement
therapy (HRT), alendronate, and raloxifene. METHODS:
A hypothetical cohort of white women aged 45–85 years,
postmenopausal, and without past incidence of osteo-
porotic fractures was treated with one of the three alterna-
tives, and tracked over 3 years in a decision model. The CE
ratio was defined as the treatment costs [e.g., medications,
monitoring, adverse events (AE)] divided by the number
of fractures averted. Treatment Willingness-To-Continue
(WTC) rate was also considered. Data were collected from
literature, expert panel survey, Medicaid claims data, and a
risk survey in the study population. Monte Carlo simula-
tions were conducted (distributions used: background risk,
cost, and risk reduction rate). Risk or probability of os-
teoporotic fracture was also divided into three strata: low
(risk 0.1), medium (0.10.3). RESULTS: Compared to no
therapy, the expected CE of HRT was $29,119 per fracture
averted, alendronate: $35,101, and raloxifene: $39,760.
The incremental CE was $42,181 for alendronate (relative
to HRT) and $85,509 for raloxifene (relative to alen-
dronate). The incremental CE of alendronate and raloxifene
were $151,981 and $697,270 among women with low risk
(43% of the sample), compared to $11,099 and $34,017
respectively among high-risk women (26% of the sample).
CE was not sensitive to discount rate and AE probabilities.
CONCLUSIONS: HRT is the most cost-effective strategy
even though it may have relatively high monitoring and AE
costs, and low WTC rate. The significant decrease in mar-
ginal costs of Alendronate and Raloxifene in high-risk
women indicates an economic condition to use these two
drugs. The study provides a framework to make risk-appro-
priate coverage decisions for chemo-preventive agents.
PAM12
COST-MINIMIZATION ANALYSIS OF THE 
TREATMENT OF RHEUMATOID ARTHRITIS 
WITH LEFLUNOMIDE IN COMPARISON WITH 
THE COMBINATION OF INFLIXIMAB AND 
METHOTREXATE
Rubio-Terrés C1, Domínguez-Gil A2
1Aventis Pharma SA, Madrid, Spain; 2Hospital Universitario de 
Salamanca, Salamanca, Spain
OBJECTIVES: To carry out a pharmacoeconomic analy-
sis to compare the efficiency of two rheumatoid arthritis
treatments in Spain. METHODS: The study consisted of
a systematic review of efficacy and toxicity as well as a
cost-minimization analysis, carried out using a pharma-
coeconomic model, comparing the treatment with leflu-
nomide and the combination of infliximab and metho-
trexate during one year. RESULTS: Clinical trials directly
comparing both treatments are not available. The re-
sponse rate ACR20 combined, after one year, was 53.0%
(CI95%: 49.2%–56.4%) with Leflunomide and 42.0%
(CI95%: 31.2%–52.5%) with the combination of Inflix-
imab and Methotrexate (P  0.051). There were no sta-
tistically significant differences in the ACR50 response
(27.0 vs 21.0, respectively; P  0.19). There were fewer
infections with Leflunomide than with the combination,
both respiratory (15.0% and 34.0%, respectively; P 
0.0003) as well as urinary (0.0% and 3.0%, respectively;
P  0.10). In the basic case, the cost per patient of a
yearly treatment with Leflunomide or with Infliximab
and Methotrexate is estimated to be 315,023 Ptas (Span-
ish pesetas) (1,893 euros, €) and 2,596,286 Ptas (15,604 €),
respectively. Therefore, the incremental cost of the com-
bined treatment would be 2,281,263 Ptas (13,711 €). The
sensitivity analysis was carried out using the minimum
and maximum costs given by the standard deviations of
the unit costs and by modifiying other variables, as no
significant differences compared to the basic case were
found. CONCLUSIONS: The cost per patient after one
year of treatment is higher with the combination of In-
fliximab and Methotrexate compared to Leflunomide,
this is basically due to the higher acquisition cost of In-
fliximab.
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OBJECTIVES: Recent studies have demonstrated slightly
improved gastrointestinal (GI) complication rates with
cyclooxygenase-2 (COX-2) inhibitors versus non-steroi-
dal anti-inflammatory (NSAID) medications in patients
not taking aspirin, however the cost avoidance from such
events alone does not justify the high costs of these
agents. Evidence that other non-GI adverse events may be
lower with COX-2 inhibitors is emerging. Since efficacy
of these agents appears to be similar, analysis of value
can be compared by evaluating adverse event profiles.
The purpose of this pharmacoeconomic model is to char-
acterize the relative cost-effectiveness of celecoxib and
rofecoxib compared to traditional NSAIDs in osteoar-
thritic patients not taking aspirin from the perspective of
the Veterans Affairs (VA) Health care System. METH-
